FTC Settles Suit, Potentially Averting Further Hurdles
Source: McAlinden Research  (9/6/23)
McAlinden Research shares a deep dive into a market driver with alpha-generating potential. More >

Contract Adding Thousands of Patients to Co.'s Telehealth Platform
Source: Streetwise Reports  (9/5/23)
This telehealth company has signed a new contract with a Texas respiratory clinic that is expected to add 10,000 new patients to its iUGO platform by mid-2024. Read to see why one analyst believes this stock is a Buy. More >

New Vaccine for Chikungunya Shown To Be Safe in Youths
Source: Edward White  (9/1/23)
The company behind the vaccine plans to use the safety data to support approvals in the U.S., European Union and Brazil, noted an H.C. Wainwright & Co. report. More >

Approved Drug for Skin Condition Shown Safe at Higher Dose
Source: Dr. Jonathan Aschoff  (9/1/23)
Based on these positive Phase 1 trial results in actinic keratosis, the biopharma developer will seek label expansion in the U.S., noted a ROTH Capital Partners report. More >

Canadian Veterinary Co. Revenue Increased to CA$12.7 Million in First Half of 2023
Source: Streetwise Reports  (8/31/23)
Grey Wolf Animal Health Corp. has announced the financial results of the last quarter. Read on to see why one newsletter writer believes this stock is worth looking into. More >

Catalyst Rich 12 Months Ahead for U.S. Biopharma Co.
Source: Scott Henry  (8/29/23)
Investors can expect to see new drug application filings, a PDUFA meeting outcome, clinical trial results and revenue stream additions, noted a ROTH Capital Partners report. More >

DNA Tech Co. Launches MRNA Platform and Files Two Patents
Source: Streetwise Reports  (8/29/23)
This company has announced the general availability of its Linea IVT platform evaluation kits and the first kit shipment to an existing Linea IVT Template customer. It has also filed two provisional patent applications for its technologies to reduce the impurities and decrease manufacturing costs for mRNA therapies like some COVID-19 vaccines. Read to see what experts are saying about the stock. More >

FDA Approves New Oncology Drug for Clinical Trials
Source: Dr. Robert Driscoll  (8/28/23)
The first in-human trial of this investigative small molecule is expected to start in Q4/23, noted a Wedbush report. More >

Telehealth Co. Launches Monitoring Program for Acute Patients
Source: Streetwise Reports  (8/18/23)
Reliq Health Technologies Inc. has launched a new post-discharge program for acute care hospitals on its iUGO platform and signed contracts in California, Florida, and Puerto Rico. More >

Co. Still Undervalued Post Solid Q2/23
Source: Scott Fortune  (8/16/23)
The multistate operator is on a growth trend and just raised its free cash flow guidance for the year, noted a ROTH Capital Partners report. More >

Med Tech Firm's Q2/23 Revenue Beats Target
Source: Scott Henry  (8/10/23)
The company is expected to gain greater market share in one segment of its business, warranting a price target increase, noted a ROTH Capital Partners report. More >

Telehealth Co. Inks Contracts With Rural Clinics in 5 States, Territories
Source: Streetwise Reports  (8/9/23)
Telehealth company Reliq Health Technologies signs contracts with 20 new rural health clinics (RHCs) in California, Nevada, Puerto Rico, Texas, and the U.S. Virgin Islands. More >

The Bond Market Has the Blues, Oil Breaks to the Upside and Moderna to the Downside
Source: Ron Struthers  (8/7/23)
The long end of the bond market is starting to price in sticky inflation, and Ron Struthers of Struthers' Stock Reports expects interest rates to rise further. Higher energy prices will start adding to inflation again, adding to the problem. Moderna has broken down on the chart and will be reporting red ink in the next few years. Time to go short. More >

Biotech Co. An Attractive Investment
Source: Clive Maund  (8/4/23)
Technical Analyst Clive Maund reviews Awakn Life Sciences Corp.'s 26-month and year-to-date charts to tell you why he believes it is an attractive investment. More >

Telehealth Co. Continues To See Soaring Revenues
Source: Streetwise Reports  (8/2/23)
This telemedicine company just had its first profitable quarter, and now it could see revenues double twice over two fiscal years. More >

Co. Works to Strengthen Itself After Merger Ended
Source: Scott Fortune  (8/2/23)
Its efforts include restructuring debt and divesting assets, noted a ROTH Capital Partners report. More >

Merger Between Two Firms Called Off
Source: Scott Fortune  (8/2/23)
The deal broke down because the parties could not sell assets that had to be divested for it to go through, noted a ROTH Capital Partners report. More >

Co. Starts Using AI on Its Telehealth Platform
Source: Streetwise Reports  (7/21/23)
This telehealth company says it has started using artificial intelligence (AI) and machine learning (ML) with two of the clients on its platform. More >

Second Half of 2023 Is Catalyst Rich for This Biopharma Co.
Source: Patrick Trucchio  (7/19/23)
The firm continues advancing its lead drug candidates, including those for anxiety and treatment-resistant depression, noted an H.C. Wainwright & Co. report. More >

Top Pick Healthcare Technology Co. Trading at Deep Discount
Source: Rob Goff  (7/19/23)
The healthcare tech firm's shares are underperforming despite two consecutive record quarters and a "landmark" contract win, noted an Echelon Capital Markets report. More >

Healthcare Tech Firm Sells Noncore Assets for $6M
Source: Rob Goff  (7/10/23)
The resulting upfront valuation gain equates to an estimated $0.02 per share, noted an Echelon Capital Markets report. More >

Approval Sought in Japan for New SARS-CoV-2 Vaccine
Source: Ed Arce  (7/7/23)
The vaccine developer's partner in Japan is already working on getting a manufacturing facility built there, noted an H.C. Wainwright & Co. report. More >

Co. Addresses Opioid Crisis Through Novel Platforms
Source: Boobalan Pachaiyappan  (7/7/23)
This California biotech, developing products that prevent opioid abuse and overdose, gained coverage by an H.C. Wainwright & Co. analyst, an initiation report noted. More >

Up to 10,000 Patients To Join Telehealth Co.s Platform in Mexico
Source: Streetwise Reports  (7/6/23)
This company is expanding its telehealth platform into Mexico, where more than 10,000 new patients are expected to be on board by next June. More >

New Psoriasis Drug Shown More Effective Than On-Market One
Source: Julian Harrison   (7/6/23)
Recent clinical trial results show the oral interleukin-23 receptor to be a "cleaner" target than non-receptor tyrosine kinase 2, noted a BTIG report. More >